<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Selected parameters of coagulation and fibrinolysis were determined in 25 postmenopausal women, treated chronically for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> with the use of <z:chebi fb="3" ids="41774">tamoxifen</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The significant influence of <z:chebi fb="3" ids="41774">tamoxifen</z:chebi> therapy on the serous fibrinolysis parameters was found </plain></SENT>
<SENT sid="2" pm="."><plain>The time of euglobulin lysis was shorter, the concentration of alpha 2-antiplasmin decreased, and plasminogen concentration increased </plain></SENT>
<SENT sid="3" pm="."><plain>The content of antithrombin III, fibrinogen, and caolin-cephalin time did not change significantly during therapy, except the prothrombin rate which increased </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="3" ids="41774">Tamoxifen</z:chebi> is an important medicine with beneficial influence on the fibrinolytic system, without affecting the serous coagulation system </plain></SENT>
</text></document>